<DOC>
	<DOCNO>NCT02371863</DOCNO>
	<brief_summary>Surgical treatment approach potentially define clinical success organic mitral valve ( MV ) regurgitation . Recurrent persistent complaint initial successful MV repair clinical challenge current practice . Especially echo parameter rest within near normal range patient present disproportionately symptomatic relation observe result . However , MV regurgitation hemodynamic disease , currently use 2-dimensional ( 2D ) transthoracic echocardiography ( TTE ) rest lack information hemodynamic change . Physical stress echocardiography promising technique complement nowadays rest TTE order improve interpretation hemodynamic change . However , normal value exercise echo lack postoperative patient cohort . A prospective , observational trial determine normal value stress echocardiographic parameter asymptomatic patient successful MV repair organic MV regurgitation , therefore highly need . Purpose SEP- study determine normal value stress echocardiographic parameter asymptomatic patient least 6 month successful MV repair organic MV regurgitation . These normal value stress echo utmost importance correctly accurate interpret stress echo result postoperative follow-up improve clinical decision making patient post MV repair .</brief_summary>
	<brief_title>Normal Values Stress Echocardiographic Parameters Patients After Successful Mitral Valve Repair Organic MR</brief_title>
	<detailed_description />
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Age â‰¥18 year ; Male female ethnicity ; At least 6 month post successful , isolated MV repair . S Asymptomatic Pulmonary hypertension &gt; 50 mmHg rest ; Atrial fibrillation ( AF ) time study related stress echo test ; Known contraindication incapability perform peak exercise inability perform physical stress testing ; LVEF &lt; 45 % ; NYHA class II . Other heart valve disease mild severity ; Concomitant surgery MV repair , e.g . MAZE , TVP procedure ; Prior heart valve surgery ; Congenital heart disease ; Disabling comorbidity , e.g . chronic obstructive pulmonary disease ( COPD ) ; Unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>